Hemophilia B is a recessive bleeding disorder that results from mutations in the coagulation factor IX
gene on the X chromosome [3-5].
CSL Behring received approval from the FDA for IDELVION [Coagulation Factor IX
(Recombinant), Albumin Fusion Protein], its novel, long-acting albumin fusion protein linking recombinant coagulation factor IX
with recombinant albumin for the treatment of hemophilia B.
IDELVION is a long-acting albumin fusion protein that links recombinant coagulation factor IX
with recombinant albumin for the treatment and prophylaxis of bleeding in patients with hemophilia B, a congenital factor IX deficiency.
Under the terms of the agreement with WFH, at least 85 percent of donated factor will be Antihemophilic Factor VIII (Recombinant), Fc Fusion Protein for the treatment of haemophilia A, with the remainder comprised of Coagulation Factor IX
(Recombinant), Fc Fusion Protein for the treatment of haemophilia B.
It is the albumin fusion protein that links recombinant coagulation factor IX
with recombinant albumin to treat haemophilia B.
Hemophilia B is caused by a deficiency of coagulation factor IX
and occurs in ~1 out of every 30,000 male births.
Active ingredient and quantity: Coagulation factor ii 400-960 iu / vial coagulation factor vii 200-500 iu / vial coagulation factor ix
400-620 iu / vial coagulation factor x 440-1,200 iu / vial other active ingredients: Protein c 300-900 iu / vial and protein s 240-760 iu / vial pharmaceutical form: Vial packaging conditions: Unit dose maximum unit price: 153 eur / vial (taxes not included) number of units planned: 450 vials estimated maximum budget: Eur 68 850 (first year of contract).
DSM Pharmaceutical Products has signed a manufacturing agreement with Sanquin Blood Supply Foundation in The Netherlands for the commercial supply of a monoclonal antibody used for the recovery and purification of coagulation factor IX
from human blood.
12 January 2012 - CSL Behring, a plasma protein therapeutics firm owned by Australian CSL Ltd (ASX:CSL), said today it had kicked off its global Phase II/III multi-centre study designed to assess the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX
with recombinant albumin (rIX-FP).
This report includes treatments for hemophilia A, B, and C, namely, recombinant factor VIII and coagulation factor IX
, and Desmopressin (DDAVP) which stimulates the release of factor VIII and also increases the level of proteins in the blood.
Contract notice: concentrate of recombinant coagulation factor ix
at least second generation.
The study Coagulation Factor IX
(CAS 9001-28-9) Market Research Report 2011' presents an overview of the Coagulation Factor IX
market globally and regionally by contemplating and analyzing its parameters.